Why These Former FDA Officials Left the Agency

Why It Matters

The exodus of veteran FDA staff undermines the agency’s capacity to safeguard drug safety, increasing risks for patients and creating regulatory uncertainty for the biotech industry.

Key Takeaways

• Massive layoffs and political pressure drove senior FDA staff out.
• Brain drain threatens FDA’s scientific expertise and regulatory continuity.
• Former officials cite opaque reassignment offers and compromised diversity values.
• Loss of mentors undermines training pipeline for future drug reviewers.
• Erosion of firewall between politics and science harms public health decisions.

Summary

The STATus Report video examines why a wave of seasoned FDA officials departed during the second Trump administration, highlighting a confluence of mass layoffs, political meddling, and cultural shifts that pushed long‑time scientists out of the agency.

Interviewees describe abrupt staff reductions in early 2022, opaque reassignment emails, and a perceived breach of the traditional firewall separating political appointees from scientific reviewers. They argue that these moves eroded morale, compromised diversity and inclusion initiatives, and accelerated a brain drain that threatens the FDA’s regulatory continuity.

One former reviewer summed it up: “I didn’t leave the FDA, the FDA left me.” Others recalled being asked to join a mysterious “patient affairs” office that never materialized, and lamented that diversity was being politicized rather than treated as sound science. The narrative also references the agency’s rapid COVID‑19 vaccine authorization, underscoring the high stakes of scientific decision‑making under pressure.

The departures have tangible consequences: fewer experienced mentors for new reviewers, delayed drug approvals, and weakened public trust in safety assessments. For pharmaceutical sponsors, the loss of institutional knowledge translates into higher compliance costs and uncertainty, while patients face potential delays in accessing safe, effective therapies.

Original Description

A year after U.S. DOGE Service cuts shook up the federal government, STAT’s FDA reporter Lizzy Lawrence has been speaking with former officials about their time at the agency. Two weeks ago, I hit the road with Lizzy to interview six of them about what drew them to the agency, the important work they did during their career there, and, ultimately, why they decided to leave during the second Trump administration. 

In a special road-trip edition of STATus Report, Lizzy and I travel around the leafy suburbs of Washington to bring you first-person testimonies, including the former director of the FDA’s Center for Drug Evaluation and Research, Richard Pazdur; Sheryl Lard-Whiteford, a leader in the FDA’s biologics center; and Julie Tierney, who worked on Operation Warp Speed.

More from STAT:

Become a subscriber: https://www.statnews.com/stat-plus/

Watch Full Episodes: https://www.youtube.com/@Statnews

Newsletters: https://www.statnews.com/signup/

STAT events: https://www.statnews.com/stat-events/

Facebook: https://www.facebook.com/statnews

Twitter: https://twitter.com/statnews

Instagram: https://www.instagram.com/status_report_ig/

Flipboard: rb.gy/3xnsxr

STAT Reports: https://rb.gy/rexfwj

STAT eBooks: https://rb.gy/eme3h5

ABOUT STAT:

Founded in 2015, STAT is a global digital media brand that focuses on delivering fast, deep, and tough-minded journalism about the life sciences industries to over six million monthly site visitors and an additional 20 million readers on the Apple News app. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry — and a revolution in human health.